Picture of Sage Therapeutics logo

SAGE Sage Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSucker Stock

Momentum

Relative Strength (%)
1m-15.86%
3m-19.76%
6m-18.57%
1yr-65.65%
Volume Change (%)
10d/3m-0.5%
Price vs... (%)
52w High-67.96%
50d MA-17.75%
200d MA-27.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-72.52%
Return on Equity-52.77%
Operating Margin-670.69%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Sage Therapeutics EPS forecast chart

Profile Summary

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 16th, 2010
Public Since
July 18th, 2014
No. of Shareholders
8
No. of Employees
487
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
60,106,687
Blurred out image of a map
Address
215 1st St, CAMBRIDGE, 02142-1213
Web
https://www.sagerx.com/
Phone
+1 6172998380
Auditors
PricewaterhouseCoopers LLP

SAGE Share Price Performance

Upcoming Events for SAGE

Q1 2024 SAGE Therapeutics Inc Earnings Release

SAGE Therapeutics Inc Annual Shareholders Meeting

Q2 2024 SAGE Therapeutics Inc Earnings Release

Similar to SAGE

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ